Despite factors that include a current population of people who are obese and do not exercise or eat as healthy as recommended, Michael Weber, MD, explains that the epidemiology of cardiometabolic conditions has improved due to the developments of more tolerable, effective pharmaceutical agents.
Dr Weber continues by discussing how there has been a decline in cardiovascular events thanks to these agents, which most notably have improved the outlook on hypertension and lipid disorders.
However, when assessing which cardiometabolic conditions have improved the most, Dr Weber concludes that diabetes is lagging behind and determines that more effective treatments for diabetes are necessary.
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests
January 29th 2023A new study estimates that prescription of standard-of-care non–small-cell lung cancer (NSCLC) therapies is lower than expected in Medicaid programs, with significant variation between states.
Read More
2 Clarke Drive
Cranbury, NJ 08512